AIRLINK 73.06 Decreased By ▼ -6.94 (-8.68%)
BOP 5.09 Decreased By ▼ -0.09 (-1.74%)
CNERGY 4.37 Decreased By ▼ -0.09 (-2.02%)
DFML 32.45 Decreased By ▼ -2.71 (-7.71%)
DGKC 75.49 Decreased By ▼ -1.39 (-1.81%)
FCCL 19.52 Decreased By ▼ -0.46 (-2.3%)
FFBL 36.15 Increased By ▲ 0.55 (1.54%)
FFL 9.22 Decreased By ▼ -0.31 (-3.25%)
GGL 9.85 Decreased By ▼ -0.31 (-3.05%)
HBL 116.70 Decreased By ▼ -0.30 (-0.26%)
HUBC 132.69 Increased By ▲ 0.19 (0.14%)
HUMNL 7.10 Increased By ▲ 0.04 (0.57%)
KEL 4.41 Decreased By ▼ -0.24 (-5.16%)
KOSM 4.40 Decreased By ▼ -0.25 (-5.38%)
MLCF 36.20 Decreased By ▼ -1.30 (-3.47%)
OGDC 133.50 Decreased By ▼ -0.97 (-0.72%)
PAEL 22.60 Decreased By ▼ -0.30 (-1.31%)
PIAA 26.01 Decreased By ▼ -0.62 (-2.33%)
PIBTL 6.55 Decreased By ▼ -0.26 (-3.82%)
PPL 115.31 Increased By ▲ 3.21 (2.86%)
PRL 26.63 Decreased By ▼ -0.57 (-2.1%)
PTC 14.10 Decreased By ▼ -0.28 (-1.95%)
SEARL 53.45 Decreased By ▼ -2.94 (-5.21%)
SNGP 67.25 Increased By ▲ 0.25 (0.37%)
SSGC 10.70 Decreased By ▼ -0.13 (-1.2%)
TELE 8.42 Decreased By ▼ -0.87 (-9.36%)
TPLP 10.75 Decreased By ▼ -0.43 (-3.85%)
TRG 63.87 Decreased By ▼ -5.13 (-7.43%)
UNITY 25.12 Decreased By ▼ -0.37 (-1.45%)
WTL 1.27 Decreased By ▼ -0.05 (-3.79%)
BR100 7,461 Decreased By -60.9 (-0.81%)
BR30 24,171 Decreased By -230.9 (-0.95%)
KSE100 71,103 Decreased By -592.5 (-0.83%)
KSE30 23,395 Decreased By -147.4 (-0.63%)

imagePARIS: Sanofi will hold a special board meeting on Wednesday at 0700 GMT to examine the French drugmaker's management structure, a source close to Sanofi told Reuters amid uncertainty over the future of its chief executive.

The board directors were hastily convened to the meeting on Tuesday evening, the source said. Representatives for Sanofi did not immediately reply to requests for comment outside of regular business hours.

Sanofi Chief Executive Chris Viehbacher had been unable to say on Tuesday whether he had the support of his board after the company's chairman declined to clarify his future during a meeting the previous day.

Several sources close to Sanofi's board told Reuters of an increasingly frosty relationship between Viehbacher and chairman Serge Weinberg, Sanofi's chairman since 2010.

Sanofi's first non-French boss, German-Canadian Viehbacher took his job in late 2008. He has transformed a very French drug company by making it much more international, winning the praise of many analysts and investors, but raising some hackles in Paris and directly butting heads with some board members over the past several months.

Les Echos newspaper this week published a letter from Viehbacher to the board, dated Sept. 4 and revealing his mistrust of Weinberg.

In the letter, Viehbacher said he had heard that Weinberg was "actively seeking a successor" to him. Viehbacher defended his track record - and urged the board to clarify his situation as soon as possible.

Sanofi's shares fell more than 10 percent on Tuesday, their biggest drop in 17 years, after the company warned its key diabetes business would probably not grow next year and as uncertainty over Viehbacher's role - which first surfaced on Monday - rattled investors.

Copyright Reuters, 2014

Comments

Comments are closed.